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Background: Identifying the complete repertoire of genes that drive cancer in 
individual patients is crucial for precision oncology. Most established methods identify 
driver genes that are recurrently altered across patient cohorts. However, mapping 
these genes back to patients leaves a sizeable fraction with few or no drivers, 
hindering our understanding of cancer mechanisms and limiting the choice of 
therapeutic interventions.  
 
Results: We present sysSVM2, a machine learning software that integrates cancer 
genetic alterations with gene systems-level properties to predict drivers in individual 
patients. Using simulated pan-cancer data, we optimise sysSVM2 for application to 
any cancer type. We benchmark its performance on real cancer data and validate its 
applicability to a rare cancer type with few known driver genes. We show that drivers 
predicted by sysSVM2 have a low false-positive rate, are stable and disrupt well-
known cancer-related pathways.  
 
Conclusions: sysSVM2 can be used to identify driver alterations in patients lacking 
sufficient canonical drivers or belonging to rare cancer types for which assembling a 
large enough cohort is challenging, furthering the goals of precision oncology. As 
resources for the community, we provide the code to implement sysSVM2 and the pre-
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Cancer is characterised by the acquisition of somatic alterations of the genome, 
the majority of which are thought to have little or no phenotypic consequence for the 
development of the disease. Identifying the genes whose alterations instead have a 
role in driving cancer (cancer drivers) is one of the major goals of cancer genomics 
and numerous methods have been developed so far to achieve this.  
Most of these methods work at the cohort-level, which means that they identify 
driver genes within a cohort of patients. For example, recurrence-based methods such 
as MutSigCV (1) and MuSiC (2) search for genes whose mutation rate (single 
nucleotide variants (SNVs) and small insertions or deletions (indels) per nucleotide) is 
above the background level. This is because mutations in cancer drivers are more 
likely to become fixed and recur across samples than those in non-driver genes. 
GISTIC2 (3) adopts a similar approach for recurrent copy number variants (CNVs). 
OncodriveCLUST (4) and ActiveDriver (5) look specifically for mutations clustering in 
hotspot positions or encoding post-translational modification sites. TUSON (6) and 
20/20+ (7) predict new drivers based on features of canonical oncogenes and tumour 
suppressors, including the proportion of missense or loss-of-function to silent 
mutations occurring across patients. dNdScv (8) computes the nonsilent to silent 
mutation ratio to identify gene mutations under positive selection, while OncodriveFM 
(9) focuses on biases towards variants of high functional impact. Finally, network-
based methods like HotNet2 (10) incorporate gene interaction networks to identify 
significantly altered modules of genes within the cohort. Albeit with different 
approaches, all these methods rely on the comparison of alterations and/or altered 
genes across patients. 
 Cohort-level methods have been of great value leading to the identification of 
more than 2,000 well-established (canonical) or candidate cancer driver genes (11, 
12). However, these approaches fail to identify rare driver events that occur in small 
cohorts or even in single patients because of low statistical power. Moreover, they are 
not ideal for application in the clinical setting because they return lists of drivers in 
entire cohorts, rather than predictions in individual patients. 
Patient-level methods ideally predict cancer drivers in each patient but are more 
challenging to implement. A few attempts such as OncoIMPACT (13), DriverNet (14) 
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and DawnRank (15) combine transcriptomic and genomic data to identify gene 
network deregulations in individual samples. Such methods require user-specified 
gene networks and deregulation thresholds, which can affect their results (13). In 
addition, matched exome and transcriptome data from the same sample are not 
always available, especially in clinical settings where shotgun transcriptomic 
sequencing is still rare. Alternative approaches such as PHIAL (16) match the patient 
mutations with databases of known clinically actionable or driver alterations but have 
a limited capacity to identify as-yet unknown driver alterations. To overcome this 
limitation, iCAGES (17) combines deleteriousness predictions and curated database 
annotations to learn features of true positive and true negative driver alterations. 
We recently developed sysSVM, a patient-level driver detection method based 
on one-class support vector machines (SVMs) (18). sysSVM learns the distinct 
molecular features (damaging somatic alterations) and systems-level features (gene 
properties) of canonical drivers. It then predicts as drivers the altered genes in 
individual patients that best resemble these features. When applied to 261 patients 
with oesophageal adenocarcinomas, sysSVM successfully identified the driver events 
in every patient (18). 
Here, we further develop sysSVM to be applied to any cancer type and 
benchmark it against other available approaches, showing that it has a lower false 
positive rate and better patient coverage. We also develop optimal models for 
identifying driver genes in all 34 cancer types available in The Cancer Genome Atlas 
(TCGA) (19) and validate them in osteosarcoma, a rare cancer type that was not part 
of TCGA. The software, optimised models and their associated driver predictions are 
provided as a resource that can be used to identify and study driver events in cancers 
at the single patient resolution.  
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IMPLEMENTATION 
 The sysSVM approach to driver detection prioritises genes with features similar 
to those of canonical cancer drivers, i.e. genes whose modifications have 
experimentally proven roles in cancer initiation and progression (Additional File 1: 
Supplementary Note). Canonical drivers differ from other human genes by an array of 
systems-level properties that define them as a group and do not strictly depend on the 
function of the single gene. These properties include gene duplicability in the human 
genome (20) and through vertebrate whole-genome duplications (21); gene 
essentiality across cell lines (11); breadth of expression in healthy tissues at the gene 
and protein levels (11, 22, 23); protein connectivity and global topology in the protein-
protein interaction network (20); participation in protein complexes (22); number of 
targeting miRNAs (21); gene evolutionary origin (21); and  protein length and domain 
organisation (22, 23) (Additional File 2: Table S1). Canonical drivers can also be 
described using molecular properties that reflect the somatic alterations that they 
acquire in cancer. These include alterations with predicted damaging effects on 
protein function (copy number gains and losses as well as truncating, non-truncating 
damaging and hotspot mutations) and overall mutational burden and copy number of 
the gene (Additional File 2: Table S1). 
To leverage the systems-level and molecular properties of canonical drivers, 
sysSVM first identifies a set of true positive canonical drivers damaged within a cohort 
of patients (Figure 1A). It then uses the features of this positive set to train one-class 
SVMs based on four kernels (linear, radial, sigmoid, polynomial). Finally, it ranks the 
remaining damaged genes in individual cancer patients with a combined score that 
weights the kernels based on their sensitivity (Additional File 1: Supplementary Note). 
Highly ranked genes have the most similar properties to those of canonical drivers and 
will be then considered the cancer drivers for that patient. We use one-class SVMs for 
sysSVM because, while canonical drivers represent a reliable set of true positives, 
identifying a true negative set of non-cancer genes is not possible. For example, 
possible negative genes could be known false positives of driver gene detection 
methods (1, 22). However, these genes are representative of false positives rather 
than true negatives, so training a classifier on them is likely to introduce unwanted 
bias. A one-class support vector machine for novelty detection is therefore an optimal 
way to solve this issue.  
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RESULTS 
Simulation of pan-cancer datasets 
In order to optimise the use of sysSVM for any cancer type, we simulated 1,000 
cancer-agnostic samples starting from all TCGA tumours with matched mutation, CNV 
and gene expression data (Additional File 1: Supplementary Methods). We ensured 
that the tumour mutation and copy number burdens were similar between real and 
simulated samples (Figure 1B) and that gene mutation and copy number status in the 
simulated dataset was the same of TCGA (Additional File 1: Figure S1A). As a result, 
the frequency of damaging alterations in known oncogenes and tumour suppressors 
was comparable between the two datasets, with TP53, PIK3CA and CDKN2A among 
the most frequently altered genes in both (Figure 1C). We further verified that gene 
alteration frequencies in the simulated data were not significantly biased by cancer 
types with large cohort sizes in TCGA (Additional File 1: Figure S1B), confirming the 
suitability of the simulated data as a representative pan-cancer cohort. 
The simulated cohort for sysSVM optimisation (hereafter referred to as the 
reference cohort) was composed of 1,000 samples with 18,455 genes damaged 
309,427 times. Of these, 686 were canonical drivers with an experimentally proven 
role in cancer (12, 24), 1,605 were candidate cancer genes from 273 cancer screens 
(11), 43 were known false positive predictions of driver detection methods (1, 25) and 
16,121 were the remaining damaged genes (hereafter referred to as the rest of genes; 
Figure 1D, Additional File 2: Table S2). We annotated seven molecular and 25 
systems-level features of all damaged genes (Additional File 2: Table S1) and used 
these features for training and prediction. As a training set, we selected 457 of the 686 
canonical drivers with proven roles as oncogenes (236) or tumour suppressors (221). 
We restricted somatic alterations of oncogenes and tumour suppressors to gain-of-
function or loss-of-function alterations, respectively (Additional File 1: Supplementary 
Methods). Since we could not reliably define the remaining 229 damaged canonical 
drivers as either oncogenes or tumour suppressors, we could not restrict their somatic 
alterations to the appropriate type. Therefore, we did not use them for training but 
could still use them for prediction and performance assessment (Figure 1D), together 
with 43 false positives and 16,121 the rest of genes.  
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sysSVM optimisation on the pan-cancer reference cohort 
Using the reference cohort, we optimised sysSVM in terms of data 
normalisation, parameter tuning and feature selection (Figure 1A). So as not to bias 
the optimisation with a particular set of kernel parameters, we implemented 512 
models with parameter combinations representing a sparse coverage of a standard 
grid search (Additional File 1: Supplementary Note). We then measured the ability of 
each of these 512 models to prioritise the 229 canonical drivers not used for training 
over the rest of damaged genes or the false positives. We did this by computing the 
Area Under the Curve (AUC) in each sample and taking the median AUC as 
representative of the whole cohort (Additional File 1: Supplementary Methods). 
First, we derived the optimal settings for data normalisation in terms of centered 
and un-centered data (Additional File 1: Supplementary Note). All models robustly 
prioritised canonical drivers above the rest using either centered or un-centered data 
but showed lower performance in distinguishing canonical drivers from false positives 
(Figure 2A). We reasoned that false positives from recurrence-based driver detection 
methods (1) shared some features with canonical drivers. For example, they encoded 
long and multi-domain proteins. When removing protein length and number of 
domains from the feature list (Additional File 2: Table S2), the performance 
substantially improved particularly for un-centred data (Figure 2B). We therefore 
removed protein length and number of domains from the model. 
Second, we selected the optimal sets of parameters in each kernel. Hyper-
parameter choice is known to have substantial impacts on classification and it is an 
open problem for one-class SVMs (26). Since the parameters for each kernel needed 
to be selected separately (Additional File 1: Supplementary Note), we could not use 
AUC of the combined multi-kernel model for assessment. Instead, we used the 
sensitivity of each kernel to predict canonical drivers calculated from three-fold cross-
validation on the training set. Sensitivity was indeed a good predictor of the overall 
AUC of canonical drivers over the rest of genes (Figure 2C) and false positives (Figure 
2D). We therefore developed an approach to select the parameters that conferred the 
highest sensitivity in multiple iterations of cross-validation (Additional File 1: 
Supplementary Methods). In the reference cohort, parameters chosen in this way 
converged within 2,000 cross-validation iterations for all kernels (Additional File 1: 
Figure S3A). 
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Finally, since the presence of highly correlated features can hinder SVM 
performance (27), we performed systematic feature selection by assessing the 
pairwise correlations between all 25 systems-level features. Four features (gene 
expression in 1≤ tissues ≤6 and in ≥37 tissues; protein expression in 0≤ tissues ≤8 
and central position in the protein-protein interaction network) exhibited a significant 
degree of inter-correlation (Pearson |r| >0.5, FDR<0.05, Additional File 1: Figure S3B). 
Removing them led to faster convergence of kernel parameters (Additional File 1: 
Figure S3A) and improved performance overall (Additional File 1: Figure S3C). 
Based on these results, we chose the default settings for the cancer agnostic 
SVM classifier, which we named sysSVM2 (28). By default, data are un-centered but 
scaled to have unit standard deviation. Six of the original systems-level features are 
excluded resulting in a total of seven molecular and 19 systems-level features (Table 
1). Finally, kernel parameters optimised on the reference cohort are provided as a 
default (Additional File 1: Figure S3A), although users may perform specific cross-
validation iterations on their own cohorts. 
We then assessed the performance of sysSVM2 in prioritising cancer drivers 
over other genes. We confirmed that, overall, the prediction scores of 229 canonical 
drivers outside the training set were significantly higher than those of any other gene 
category (Figure 2E). Candidate cancer genes also scored significantly higher than 
the rest of genes, indicating that they were also in top ranking positions. We also 
measured the relative ranks of genes in individual samples using Receiver Operating 
Characteristic (ROC) curves. Comparing canonical drivers to the rest of genes and to 
false positives gave AUCs of 0.73 and 0.93, respectively (Figure 2F), demonstrating 
that canonical drivers were prioritised above the rest of genes and especially above 
false positives. This was not surprising as the properties of canonical drivers differ 
substantially from those of false positives (Additional File 1: Figure S3D), further 
supporting that known false positives are not representative of non-cancer genes. 
 
Effect of training cohort size on sysSVM2 performance  
The sample size of patient cohorts can highly vary across cancer types. For 
example, in TCGA it ranges from 32 samples for diffuse large B-cell lymphoma (DLBC) 
to 726 for breast cancer (BRCA, Additional File 2: Table S3), with a median of 201 
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samples. We therefore sought to address how the sample size of the training cohort 
affected sysSVM2 performance.  
Starting from all TCGA samples and using the previously described approach, 
we simulated 40 training cohorts, ten of which were composed of ten samples, ten of 
100 samples, ten of 200 samples and ten of 1,000 samples. We then trained sysSVM2 
on each of these 40 cohorts independently and used the resulting models to rank 
damaged genes in the reference cohort and to compare their performance.  
The distributions of AUCs of canonical drivers over the rest of genes or false 
positives were high for all four cohort sizes (Figure 3A). This suggested that sysSVM2 
was overall very effective in prioritising cancer genes independently of the training 
cohort size. We then compared the composition of the prioritised gene list in each 
sample across models of a given size. We measured a composition score of the top 
five genes accounting for the number and position of canonical drivers, candidate 
cancer genes and false positive genes (Additional File 1: Supplementary Methods). 
Similar to the AUC, the composition score of the top five genes was also very similar 
across training cohorts (Figure 3B). However, a few models trained on ten or 100 
samples returned false positives in the top five positions while no false positives were 
predicted by models trained on larger cohorts of 200 or 1,000 samples.  Finally, we 
measured the ratio between observed and expected canonical drivers and false 
positives in the top five genes (Figure 3C, Additional File 1: Supplementary Methods). 
Independently of the training cohort size, false positives in the top five genes were 
always lower than expected, confirming that sysSVM2 efficiently distinguished false 
positives from drivers. The number canonical drivers in the top five genes was more 
than twice the expected number in >85% of samples and more than five times the 
expected value in around 65% of samples. As with the other metrics, the performance 
of sysSVM2 did not change substantially with the size of the training cohort. 
Since we used the same reference cohort for prediction, we could directly 
compare the gene ranks in each patient across models, thus assessing their prediction 
stability. To do so, we measured the Rank-Biased Overlap (RBO) score that compares 
two ranked lists giving greater weight to the higher-ranked positions (29) (Additional 
File 1: Supplementary Methods).  The distributions of RBO scores of the top five genes 
were significantly higher for large training cohorts compared to those composed of ten 
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samples (Figure 3D). Moreover, models trained on large cohorts showed overall 
higher gene overlap in the top five genes (Figure 3E).  
These results showed that, although sysSVM2 successfully separates 
canonical drivers from other genes independently of the training cohort size, small 
cohorts lead to occasional false positive predictions and to unstable gene ranking. 
Since the median cohort size of TCGA cancers is 201 samples, sysSVM2 is likely to 
separate canonical drivers from the rest of genes with a very low false positive rate 
and stable gene rankings for most cancer cohorts.  
 
Benchmark of sysSVM2 against existing methods 
Next, we sought to compare the predictions of sysSVM2 on real cancer data to 
those of other driver detection methods. To do this, we used 657 Gastro-Intestinal (GI) 
adenocarcinomas from TCGA (73 oesophageal, 279 stomach, 219 colon and 86 rectal 
cancers, Additional File 2: Table S3). Overall, this cohort had 17,122 unique damaged 
genes, including 438 tumour suppressors and oncogenes used for sysSVM2 training 
(Additional File 2: Table S2). After ranking the remaining 16,684 damaged genes, we 
confirmed the overall ability of sysSVM2 to prioritise the 228 canonical drivers not used 
for training over the rest of damaged genes and false positives also in real data (Figure 
4A).  
To identify the list of cancer drivers of each patient, we adopted a top-up 
approach. Starting from the GI canonical drivers (11) damaged in each sample, we 
added sysSVM2 predictions progressively based on their rank to reach five drivers per 
patient (Additional File 1: Supplementary Methods). This was based on the 
assumption that each cancer requires at least five driver events to fully develop, in 
concordance with recent quantifications of the amount of excess mutations arising 
from positive selection in cancer (8, 30). While 154 patients had damaging alterations 
in five or more GI canonical drivers, 503 patients (77%) needed at least one prediction 
(Figure 4B), highlighting the need for additional cancer driver predictions. This resulted 
in 564 unique sysSVM2 drivers.  
We then predicted the drivers in the same GI samples using two cohort-level 
(PanSoftware (31) and dNdScv (8)) and two patient-level (OncoIMPACT (13) and 
DriverNet (14)) detection methods. PanSoftware integrated 26 computational driver 
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prediction tools and we took the list of 40 damaged drivers directly from the original 
publication (31), given that we used a large subset (87%) of the same TCGA GI 
samples. We ran the other three methods with default parameters (Additional File 1: 
Supplementary Methods) and obtained 25 predicted drivers with dNdScv, 607 with 
DriverNet and 1,345 with OncoIMPACT.  
We compared sysSVM2 to the four other methods in terms of recall rates of 
canonical drivers or false positives, proportion of novel predictions and patient driver 
coverage. Overall, cohort-level methods had higher recall rates of GI canonical 
drivers, fewer novel predictions and a comparably low false positive recall than 
sysSVM2 (Figure 4C). However, unlike sysSVM2, neither cohort-level method 
predicted drivers in all patients, leaving the vast majority of them with less than five 
predictions and some with no predictions (Figure 4D). 
Compared to sysSVM2, the other two patient-level methods had higher recall 
rates of the 228 canonical drivers, a comparably high proportion of novel predictions 
but higher false positive rate (Figure 4C). Namely, sysSVM2 made only one false 
positive prediction in one patient while DriverNet and OncoIMPACT predicted four and 
seven false positives in 124 and 306 patients, respectively (Additional File 1: Figure 
S4A). Overall, all three methods had high patient driver coverage, but sysSVM2 
outperformed the other two with only one sample where it predicted less than five 
drivers (Figure 4D). Interestingly, the overlap of predictions between sysSVM2 and 
the other patient-level methods was statistically significant (Additional File 1: Figure 
S4A) even when only top-up predictions were considered (Additional File 1: Figure 
S4B). This suggested that the majority of predictions converged to the same genes. 
These results showed that cohort-level methods have high specificity and 
sensitivity to identify cancer-specific canonical drivers but often fail to find drivers in a 
substantial subset of patients. Compared to other patient-level detection methods, 
sysSVM2 outperforms them in terms of specificity and patient coverage.  
 
Compendium of sysSVM2 models and patient-level drivers in 34 cancer types 
In order to provide a comprehensive resource of trained models (28) and 
patient-level drivers, we sought to apply sysSVM2 to 7,646 TCGA samples of 34 
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cancer types with at least one somatically damaged gene (Additional File 1: 
Supplementary Methods).  
To find the best training setting for the algorithm on real cancer samples, we 
compared the performance of sysSVM2 trained on the whole pan-cancer cohort as 
well as on the 34 cancer types separately. In the pan-cancer setting, we used all 477 
tumour suppressors and oncogenes damaged across the whole cohort. In the cancer-
specific setting, we used instead only the subsets of these genes damaged in each 
cancer type (Additional File 2: Table S3). We then predicted on the remaining 
damaged genes and applied the top-up approach as described above, starting from 
the cancer-specific canonical drivers damaged in each patient (Additional File 2: Table 
S3). We found that 6,067 samples (79%) required at least one sysSVM2 prediction in 
order to reach five drivers (Figure 5A). These corresponded to 4,369 and 4,548 unique 
genes in the pan-cancer and cancer-specific settings, respectively, with a significant 
overlap of predictions (3,896, p <2.2x10-16, two-sided Fisher’s exact test). 
We then compared the performance of pan-cancer and cancer-specific settings 
of sysSVM2 in prioritising canonical drivers over rest of genes or false positives. The 
AUCs differed significantly (FDR <0.05) and substantially (|difference in medians| 
>0.05) in only five cancer types (Figure 5B, Additional File 1: Figures S5A and S5B). 
All of them were composed of small cohorts with <200 samples and in all cases the 
pan-cancer setting showed better performance than the cancer-specific setting. The 
composition score of the top five predictions also differed significantly and 
substantially (|difference in medians| >1) in only three cancer types (Figure 5C, 
Additional File 1: Figure S5C). All these cancer types were again characterised by 
small training cohorts and showed higher performance in the pan-cancer setting. 
Predictions of cancer-specific models and the pan-cancer model were mostly similar, 
with the exception of cancer types with small training cohorts (Additional File 1: Figures 
S5D and S5E). Overall, these results confirmed the trend observed in the simulated 
data and indicated that the pan-cancer and cancer-specific settings performed 
similarly well in most cases, except for small cohorts where the pan-cancer model 
performed better. 
Based on these results, we used the pan-cancer setting for cancer types with 
small cohorts (N <200) and the cancer-specific setting for the others, as this could 
reflect cancer-type specific biology without jeopardising performance or stability. The 
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final list of patient-specific predictions in 34 cancer types was composed of 4,470 
unique genes, the vast majority of which (93%) were rare (<10 patients) or patient-
specific (Figure 5D, Additional File 2: Table S4). A gene set enrichment analysis on 
these genes revealed 984 enriched pathways overall (Reactome level 2 or above, 
FDR <0.01, Additional File 1: Supplementary Methods, Additional File 2: Table S5). 
Interestingly, when mapping these pathways to broader biological processes 
(Reactome level 1), a few processes were widely enriched in almost all cancer types 
(Figure 5E). These included well-known cancer-related processes such as chromatin 
organisation (32), DNA repair (33), cell cycle (34) and signal transduction (35). 
Therefore, although not recurring across patients, sysSVM2 predictions converged to 
perturb similar biological processes that are known to contribute to cancer. 
 
sysSVM2 predictions in an independent cancer cohort 
We finally sought to assess whether the sysSVM2 models trained on TCGA 
could be applied for driver prediction in a cancer type not included in TCGA. We 
therefore analysed 36 osteosarcomas from the Pan-Cancer Analysis of Whole 
Genomes (PCAWG) consortium (30). Osteosarcoma is a rare, genetically 
heterogeneous bone cancer with poor prognosis and only six well-established 
canonical drivers (36, 37).  
We annotated the genomic data of the PCAWG cohort finding 4,969 damaged 
genes overall with a median of 93 damaged genes per sample (Additional File 2: Table 
S2). Only two of these samples had three damaged osteosarcoma canonical drivers 
while 19 (53%) of them had no canonical driver (Figure 6A), highlighting the need for 
further predictions. Given the small cohort size, we used the TCGA pan-cancer setting 
to rank the damaged genes in each osteosarcoma. Considering the top five predictions 
per sample, we got 129 unique genes (Additional File 2: Table S6), which were poorly 
recurrent across samples (Figure 6B), reflecting again the genetic heterogeneity of 
osteosarcoma. 
At the cohort level, sysSVM2 predictions included five of the six (83%) 
osteosarcoma canonical drivers (36, 37). At the patient level, the six osteosarcoma 
canonical drivers were damaged 27 times and in 14 of these cases (53%) they were 
in the top five predictions (Figure 6C). This proportion rose to 81% when considering 
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the top ten predictions. In addition to osteosarcoma canonical drivers, 26 sysSVM2 
predictions were canonical drivers in other cancer types, 16 were candidate cancer 
driver genes and 81 had no previously known involvement in cancer (Additional File 
2: Table S6). Despite this, these 81 genes were enriched in eight pathways (FDR 
<0.1), most of which have a known role in cancer (Figure 6D). Moreover, they included 
genes known to promote osteogenesis such as YAP1 and YES1 (38, 39). 
These results showed that sysSVM2 is able to identify reliable cancer drivers 
in individual patients even for cancer types not used for training. This has relevant 
implications particularly in the case of rare cancers that are poorly studied and have 
little genomic data available.  
 
DISCUSSION 
Identifying the complete repertoire of driver events in each cancer patient holds 
great potential for furthering the molecular understanding of cancer and ultimately for 
precision oncology. While many recurrent driver genes have now been identified, the 
highly heterogeneous long tail of rare drivers still poses great challenges for detection, 
validation and therapeutic intervention. 
Our method allows to identify driver genes in individual patients. These genes 
converged to well-known cancer-related biological processes and further studies could 
potentially use these predictions to investigate particular aspects of cancer biology, 
such as driver clonality and their progressive acquisition during cancer evolution. 
Extending the algorithm with additional sources of data is another avenue for future 
work. For example, transcriptomic and epigenomic data could enhance the ability of 
sysSVM2 to identify driver events. Additionally, recent efforts have identified a large 
number of driver events in non-coding genomic elements (30). Given such a training 
set of true positives, sysSVM2 could be further developed to identify non-coding 
drivers in individual patients, as long as appropriate features could be identified. The 
general approach of identifying drivers using a combination of molecular and systems-
level properties affords great flexibility for such developments.  
It is increasingly common for sequencing studies to integrate multiple tools for 
driver detection (31), since building a consensus can make results robust to the 
weaknesses of individual methods. sysSVM2 also has its weaknesses. For example, 
 15 
while systems-level properties distinguish cancer genes as a set, there are some 
cancer genes that do not follow this trend (11) and are thus likely to be missed by the 
algorithm. Our approach in the current work of topping up known driver genes with 
predictions from sysSVM2 is a simple example of how sysSVM2 can be used in 
conjunction with other approaches. More broadly, it is likely the case that patient-level 
driver detection will eventually rely on an entire ecosystem of different methods. In this 
work, we have demonstrated that there is a place for sysSVM2 in such an ecosystem. 
 
CONCLUSIONS 
In this work, we developed a cancer-agnostic algorithm, sysSVM2, for 
identifying cancer driver in cancer individual patients (28). By refining the machine 
learning approach upon which the original algorithm was built (18), we broadened its 
applicability to the pan-cancer range of malignancies represented in TCGA. sysSVM2 
successfully and stably prioritises canonical driver genes for most publicly available 
cancer cohorts. For those composed of fewer samples, the models optimised on the 
whole pan-cancer dataset offer a valid alternative. Moreover, compared to other 
patient-level driver detection methods, sysSVM2 has better patient coverage and a 
particularly low rate of predicting established false positives. sysSVM2 can be used to 
identify driver alterations in individual patients and rare cancer types where canonical 
drivers are insufficient to explain the onset of disease, as we have validated in 
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Figure 1. sysSVM approach for driver prioritisation 
 
A. Overview of sysSVM. Molecular (somatic SNVs, indels and mutation burden) and 
systems-level features (Additional File 2: Table S1) of damaged canonical drivers in 
the analysed samples are used for training. The best models of support vector 
machines (SVMs) with four kernels are selected using cross-validation and trained on 
the whole set of damaged canonical drivers. Finally, a combined score is used to 
prioritise driver genes in individual patients. The SVM implementation was generalised 
for optimal performance on a simulated cancer-agnostic dataset through data 
normalisation, parameter tuning and feature selection.  
B. Generation of a simulated reference cohort from TCGA data. Values of damaging 
mutation burden and ploidy were randomly assigned to samples. Damaged genes 
were then extracted from real samples with similar values of damaging mutation 
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burden (+/-10% for mutations) and ploidy (+/-0.1 for CNVs). Dots represent individual 
TCGA (orange) or simulated (yellow) samples. Red lines indicate average numbers of 
genes with damaging mutations or CNVs in TCGA samples, for each given values of 
damaging mutation burden or ploidy.  
C. Frequencies of canonical drivers in real and simulated samples. Oncogene gain-
of-function, tumour suppressor loss-of-function and both types of TP53 alterations 
were considered. 
D. Gene sets used for sysSVM optimisation. The training set included oncogenes 
(OGs) and tumour suppressor genes (TSGs), as well as TP53. All other damaged 
genes were used for prediction and assessment. These included other canonical 
drivers (without a proven OG or TSG role), candidate cancer genes from published 
cancer sequencing screens, known false positives of established driver detection 
methods and the remaining damaged genes. Bars indicate the number of unique 
damaged genes across the reference cohort of 1,000 simulated samples.  
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Figure 2. sysSVM optimisation on the simulated reference cohort 
 
Model performances on the reference cohort using centered (left) and un-centered 
(right) data with all 25 systems-level features (A) or excluding protein length and 
number of protein domains (B). A sparse grid of 512 parameter combinations in the 
four kernels was tested. The performance of each model was measured using the 
Area Under the Curve (AUC), comparing the ranks of canonical drivers to the rest of 
genes and false positives. Median AUC values across all samples were plotted. Red 
dotted lines represent the minimum AUC values.  
Correlation between model average sensitivity and AUCs of canonical drivers over the 
rest of genes (C) or false positives (D). The sensitivity of each kernel was measured 
on the training set over 100 three-fold cross-validation iterations. The median values 
over the four kernels are plotted. R and p-values from Pearson’s correlation test are 
reported. Dotted red lines indicate the linear regression curves of best fit. 
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E. Distributions of sysSVM2 prediction scores for different types of damaged genes in 
the reference cohort. Whiskers extend to 1.5 times the Inter-Quartile Range (IQR). 
Statistical significance was measured using two-sided Wilcoxon tests. The median 
values of the distributions are labelled. **** = p <2.2x10-16.  
F. Receiver Operating Characteristic (ROC) curves, comparing canonical drivers to 
the rest of genes (green) and to false positives (brown). Recall rates were calculated 
for each sample separately and the median ROC curve across samples was plotted. 
Median Areas Under the Curve (AUCs) for both comparisons are also indicated.  
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Figure 3. Effect of cohort size on sysSVM2 performance 
 
A. Distributions of AUCs comparing the ranks of canonical drivers to the rest of genes 
(green) and False Positives (brown). Models were trained on ten simulated cohorts 
composed of ten, 100, 200 and 1,000, for a total of 40 simulated cohorts. These were 
then used to predict on the same reference cohort of 1,000 samples. The AUC was 
measured for each set of predictions in each sample. 
B. Distributions of composition scores of the top five predictions in terms of canonical 
drivers, candidate cancer genes, false positives and rest of genes (Additional File 1: 
Supplementary Methods). The composition score was measured for each set of 
predictions in each sample. Six training cohorts of size ten and two cohorts of size 100 
gave negative composition scores in at least one sample, indicating highly ranked 
false positive genes. 
C. Ratios between observed and expected numbers of canonical drivers and false 
positives in the top five predictions (O/E ratios). For each size of the training cohort, 
the percentages of samples with a false positive O/E ratio of zero and canonical driver 
O/E ratios greater that 2, 5 and 10 are shown (Additional File 1: Supplementary 
Methods). 
D. Rank-Biased Overlap (RBO) score of the top five predictions in each sample 
(Additional File 1: Supplementary Methods). RBO scores measured the similarity 
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between the predictions from every possible pair of models trained on cohorts of a 
particular sample size. Statistical significance was measured using two-sided 
Wilcoxon tests. **** = p <2.2x10-16. 
E. Distribution of the number of top five predictions shared between models trained 
with the same cohort size. The overlap was calculated between each pair of 
predictions in each sample.  
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Figure 4. sysSVM2 benchmark on TCGA gastro-intestinal cancers  
 
A. Median Receiver Operating Characteristic (ROC) curves across 657 Gastro-
Intestinal (GI) samples from TCGA. Curves compare the ranks of canonical drivers to 
the rest of genes or to false positives. The median Areas Under the Curve (AUCs) are 
also indicated. 
B. Distribution of GI canonical drivers across the GI cohort. Lists of canonical drivers 
for each GI cancer type were obtained from NCG6 (11) and mapped to samples of the 
corresponding cancer type where they were damaged. Numbers of samples are 
indicated above each bar. Samples with five or more GI drivers did not require 
additional driver predictions.  
C. Comparison of performance between sysSVM2 and four other driver detection 
methods. The set of unique drivers predicted by each approach were compared in 
terms of recall of GI canonical drivers, other canonical drivers (non-GI and outside the 
sysSVM2 training set) and false positives and proportion of novel predictions not 
previously associated with a cancer driver role. The number of genes in each category 
is reported in brackets. The recall of GI canonical drivers could not be assessed for 
sysSVM2 because these were part of the training set. They were however considered 
as drivers by default, rather than predicted by the algorithm. NA = Not Applicable. 
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D. Proportions of 657 GI samples left with no predicted drivers (left) or fewer than 5 
predictions. The one sample left with fewer than 5 predictions by sysSVM2 (TCGA-
FP-8210, stomach cancer) had four damaged genes overall.  
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Figure 5. sysSVM2 predictions in 34 cancer types  
 
A. Number of damaged canonical drivers per sample. Lists of canonical drivers for 
each cancer type were obtained from NCG (11) and mapped to samples of the 
corresponding cancer type. 6,067 samples with less than five canonical drivers 
damaged underwent the top-up procedure to reach five drivers. 
Difference in Areas Under the Curve (AUCs) between the pan-cancer and cancer-
specific settings in ranking canonical drivers over the rest of human genes and false 
positives (B) and in the composition score of the top five predictions (C). The median 
values of the distributions in each cancer type were used for comparison, with the 
yellow and blue regions indicating better performance in the pan-cancer and cancer-
specific settings, respectively. The number of samples used for training is indicated on 
the x-axis. Colour dots represent cancer types where the two settings differ both 
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significantly (FDR <0.05, Wilcoxon rank-sum test) and substantially (|difference in 
medians| >0.05 for AUCs, >1 for composition score). ACC, adrenocortical carcinoma; 
TGCT, testicular germ cell tumours; PAAD, pancreatic adenocarcinoma; READ, 
rectum adenocarcinoma; MESO, mesothelioma; UVM, uveal melanoma; and OSCC, 
oesophageal squamous cell carcinoma. 
D. Recurrence of damaging alterations in 282 canonical driver genes and 4,470 
sysSVM2 top-up predictions across 7,646 samples. 
E. Gene set enrichment analysis of sysSVM2 top-up genes, grouped in broad 
biological processes (Reactome level 1). Numbers of pathways enriched in at least 
one cancer type out of the total pathways tested are reported in brackets. Red vertical 
strokes indicate the mean number of cancer types that pathways from each broad 
process are enriched in (bottom x-axis). 
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Figure 6. Validation of sysSVM2 in osteosarcoma  
 
A. Distribution of osteosarcoma canonical drivers across the PCAWG osteosarcoma 
cohort. Lists of canonical drivers for osteosarcoma derived from the literature (36, 37) 
and mapped to samples where they were damaged. Numbers of samples are 
indicated above each bar.  
B. Recurrence of the 129 sysSVM2 predictions across the PCAWG osteosarcoma 
cohort. The percentages of genes that are predicted in 1, 2 and ≥3 are shown. 
C. Patient-level predictions of osteosarcoma canonical drivers by sysSVM2 when 
considering the top five genes. The number of samples in which each canonical driver 
is damaged (yellow) and predicted as a driver by sysSVM2 (pink) is shown. 
D. Gene set enrichment analysis of 81 sysSVM2 predictions with no previously 
reported involvement in cancer. Reactome level 2 and above were considered and 
pathways with FDR <0.1 are shown. 
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Category Property Feature Type 
Molecular 
Gene mutation 
Mutational load (n) Continuous 
Non-truncating damaging mutations (n)  Continuous 
Truncating mutations (n) Continuous 
Hotspot mutations (n) Continuous 
Gene copy number  
Gene copy number (n) Continuous 
Gene is amplified Binary 
Gene is deleted Binary 
Systems-level 
Gene duplication 
Gene is duplicated Binary 
Gene is an ohnolog  Binary 
Gene essentiality 
Cell lines in which gene is essential (%) Continuous 
Gene is essential  Binary 
Gene expression 
Tissues expressing gene (n) Continuous 
Gene is expressed in 0 tissues Binary 
Gene is expressed in 7≤ tissues≤ 36 Binary 
Protein expression 
Tissues expressing protein (n) Continuous 




PPIN degree Continuous 
Protein is a PPIN hub Binary 
PPIN betweenness Continuous 
PPIN clustering coefficient Continuous 
Protein complexes Complexes the protein is part of (n) Continuous 
miRNA interactions miRNAs targeting the gene (n) Continuous 
Gene evolutionary 
origin 
Pre-metazoan origin Binary 
Metazoan origin Binary 
Vertebrate origin Binary 
Post-vertebrate origin Binary 
 
Table 1: Twenty-six features derived from molecular and systems-level properties of genes 
and used to predict cancer drivers in sysSVM2. Molecular properties describe gene alterations 
in individual cancer samples. Systems-level properties are global gene properties (see also 
Additional File 2: Table S1). PPIN: Protein-protein interaction network. miRNA: micro RNA.  
 
 
 
 
 
 
 
